VivoSeq
Other

Newborn Respiratory Distress Syndrome

8

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Newborn Respiratory Distress Syndrome is an early-stage landscape with 8 programs across 4 companies. The most active players are Salix, Fresenius Kabi Oncology Ltd., Kaken Pharmaceutical. 4 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

0/100

Mech. Concentration

43/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Salix

1 program

ApprovedF

Fresenius Kabi Oncology Ltd.

1 program

ApprovedK

Kaken Pharmaceutical

1 program

PreclinicalM

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

1

clinical trials

Unknown status1 · 100%

Clinical Trials

Trial Activity

Intratracheal Vitamin A Administration With Surfactant for Newborn Respiratory Distress Syndrome
Unknown status·TThird Military Medical University·Phase 3·NCT01265589·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)